Variable | Median OS (95% CI) (months) | p-value | |
Age (years) |
|
| |
≥60 | 18 (5.47 - 30.52) | <0.0001* | |
Consultation delay (months) |
|
| |
7 - 12 | 49 (42.73 - 55.26) | 0.032* | |
>12 | 30 (20.79 - 39.20) | <0.0001* | |
Tumor size |
|
| |
T3 | 35 (50.00 - 73.99) | 0.006* | |
T4 | 18 (9.39 - 26.60) | <0.0001* | |
Lymph node metastasis (N) |
|
| |
N2 | 50 (47.31 - 52.68) | <0.0001* | |
N3 | 24 (14.65 - 33.93) | <0.0001* | |
Distant Metastasis (M) |
|
| |
yes | 30 (17.12 - 42.85) | 0.041* | |
Stage |
|
| |
III | 50 (47.24 - 52.75) | 0.002* | |
IV | 20 (10.70 - 29.29) | <0.0001* | |
Treatment |
|
| |
Palliative chemotherapy | 24 (15.31 - 32.68) | <0.001* | |
Type of radiotherapy |
|
| |
Conformational | 44 (38.13 - 49.86). | <0.001* | |
Radiation therapy dose |
|
| |
≥65 Gy | 51 (45.05 - 56.94) | <0.001* | |
Staggered radiotherapy |
|
| |
≥6 weeks | 51 (45.42 - 56.57) | <0.001* | |
Chemotherapy protocol |
|
| |
CDDP + Doxoribucin | 88 (15.0 - 161) | 0.027* | |